论文部分内容阅读
Background: 18-Fluorodeoxyglucose positron emission tomography(PET) is used c linically to detect recurrent colon cancer after surgical resection, but the sen sitivity of PET for premalignant colon lesions and early stage colon cancer is n ot well defined. Methods: In a prospective study, 45 patients with a total of 58 colonic neoplasms, including premalignant polyps, premalignant, flat lesions, a nd early stage cancers, were evaluated by PET. Results: The sensitivity of PET f or cancer was 62%(8/13). PET detected 100%(7/7) of cancers 2 cm or larger but only 17%(1/6) of cancers smaller than 2 cm.PET detected 23%(3/13) of flat, pre malignant lesions; 70%(7/10) of protruded, premalignant lesions 3 cm or larger; 38%(3/8) of protruded, premalignant lesions between 2 and 2.9 cm;and 14%(2/14 ) of protruded, premalignant lesions between 1 and 1.9 cm. There was no false-p ositive PET reading. Conclusions:PET has limited sensitivity for flat, premalign ant lesions;protruded, premalignant lesions smaller than 3 cm; and colon cancers smaller than 2 cm.
Background: 18-Fluorodeoxyglucose positron emission tomography (PET) is used c linically to detect recurrent colon cancer after surgical resection, but the senitivity of PET for premalignant colon lesions and early stage colon cancer is n ot well defined. Methods: In a prospective study: 45 patients with a total of 58 colonic neoplasms, including premalignant polyps, premalignant, flat lesions, a nd early stage cancers, were evaluated by PET. Results: The sensitivity of PET f or cancer was 62% (8/13). PET detected 100% (7/7) of cancers 2 cm or larger but only 17% (1/6) of cancers smaller than 2 cm. PET detected 23% (3/13) of flat, pre malignant lesions; 70% ( (10 of 7) of protruded, premalignant lesions 3 cm or larger; 38% (3/8) of protruded, premalignant lesions between 2 and 2.9 cm; and 14% (2/14) of protruded, premalignant lesions between 1 and 1.9 cm . There was no false-p ositive PET reading. Conclusions: PET has limited sensitivity for flat, premalignant ant lesions; protruded, premalignant lesion s smaller than 3 cm; and colon cancers smaller than 2 cm.